产后胎盘细胞遗传学分析揭示结构染色体异常的起源
该回顾性诊断研究对31例NIPT提示结构染色体异常但胎儿随访正常或异常不同的产后胎盘进行SNP array分析,18例(58%)胎盘确认了NIPT所见异常,其中7例(39%)存在复杂胎盘-胎儿嵌合体,提示NIPT结构异常需全基因组胎儿随访。
要点
- NIPT结构异常而胎儿随访正常时,应行全基因组而非靶向胎儿检查。
- 产后胎盘CTB与MC分离分析可揭示结构异常的胚胎起源。
- 复杂染色体 rearrangement 可持久存在于成熟胎盘和胎儿。
核心结论
- NIPT提示结构染色体异常而胎儿随访正常或不同时,产后胎盘全基因组分析可在58%(18/31)病例确认该异常,其中39%(7/18)为复杂胎盘-胎儿嵌合体。
主要发现
- 18/31例(58%)在一个或多个胎盘活检中确认NIPT所检出的结构染色体异常。
- 13/31例(42%)未确认NIPT异常,但其中1例在两次活检的CTB中发现看似无关的异常。
- 11/18确认例中胎盘与NIPT异常相同,均为染色体正常胎儿伴胎盘局限性异常。
- 7/18确认例中NIPT异常涉及复杂嵌合体,含不同异常细胞系;其中4例胎儿携带与NIPT不同的致病性异常,3例胎儿携带相关良性异常。
关键数值与推荐
- SNP array分析评估拷贝数变异≥0.5 Mb和纯合区域≥3 Mb。
- 每胎盘取2–4份绒毛活检,酶解分离为细胞滋养层(CTB)和间充质核心(MC)。
临床怎么用
- NIPT结构异常后胎儿随访应采用全基因组方法,避免遗漏其他异常。
- 遗传咨询应告知胎儿可能携带其他相关结构异常,不仅限于NIPT所检出的异常。
- 看似意义不明的结构异常可能揭示胎儿真正致病性异常,所有潜在病例均应随访。
- 产后胎盘CTB与MC分离分析可提供结构异常胚胎起源的关键信息。
局限性
- 未进行常规核型、FISH或全基因组测序,复杂胎盘-胎儿嵌合体机制仅为推测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can comprehensive cytogenetic follow-up of the placenta post-partum uncover possible explanations for discrepancies between non-invasive prenatal testing (NIPT) showing structural chromosomal aberrations and foetal follow-up showing normal results or other chromosomal aberrations? SUMMARY ANSWER: In 18/31 (58%) cases of structural chromosomal aberrations detected with NIPT, where foetal and maternal follow-up was normal or the foetus had another chromosomal aberration, genome-wide examination of term placental chorionic villi confirmed the discrepancy and in 7/18 (39%) confirmed cases complex foeto-placental mosaicism was found. WHAT IS KNOWN ALREADY: Complex chromosomal rearrangements are often seen in single-cell studies of preimplantation embryos, but it is unknown if these persist into the mature placenta. Confined placental mosaicism explains most discordant NIPTs involving a trisomy, but little is known about structural chromosome aberrations. STUDY DESIGN, SIZE, DURATION: We performed a retrospective diagnostic test study of cytogenetic follow-up data from post-partum placentas. We included data from pregnancies where (i) NIPT showed a structural aberration, (ii) follow-up of foetus (amniotic fluid and/or cord blood) and mother (genomic DNA and/or cfDNA after birth) was normal or the foetus showed another chromosomal aberration, (iii) follow-up was performed in the Erasmus MC, (iv) more than one sample from the post-partum placenta was analysed, and (v) samples were of good quality (not in formaldehyde, sufficient material).In the period from January 2014 to March 2022, 115 231 NIPTs were performed in the Erasmus MC; 217 of these showed structural chromosomal aberrations and 123 were followed up in the Erasmus MC (inclusion criteria 3). After exclusion of the foetal (same aberration as with NIPT) and maternal structural chromosome aberrations, 48 placentas were requested to elucidate the discrepancies seen between NIPT (abnormal) and foetal karyotype (normal or differently abnormal; inclusion criteria 1-2). Of these, 31 met criteria 4 and 5 and were included in this study. PARTICIPANTS/MATERIALS, SETTING, METHODS: In a diagnostic setting, we performed a cytogenetic analysis of postpartum placentas in order to confirm confined placental mosaicism in 31 cases in which NIPT showed a structural chromosome aberration. Two to four chorionic villus biopsies were taken per placenta, and separated enzymatically into cytotrophoblast (CTB) and mesenchymal core (MC) and analysed using SNP arrays. In our analysis, cases were assessed for copy number variants ≥0.5 Mb and regions of homozygosity ≥3 Mb. MAIN RESULTS AND THE ROLE OF CHANCE: In 18/31 cases (58%), we could confirm the structural chromosome aberration detected with NIPT in one or more placental biopsies. In 13/31 cases (42%), the structural chromosomal aberration detected with NIPT was not confirmed, but in one case an apparently unrelated aberration was found in the CTB of two biopsies. In 11/18 confirmed cases, the same aberration as detected with NIPT, was confirmed in the placenta. All these cases concerned chromosomally normal foetuses with a chromosome aberration confined to the placenta. In one case, an extra, apparently unrelated, aberration was found in one placental biopsy. In 7/18 confirmed cases, the aberration detected with NIPT was confirmed in the placenta and showed to be involved in complex mosaicism involving different abnormal cell lines. In four of these seven cases, the foetus was affected with a pathogenic chromosome aberration that was different from the NIPT aberration. In three cases, a related but benign chromosome aberration was present in the foetus. LIMITATIONS, REASONS FOR CAUTION: As conventional karyotyping, FISH or whole genome sequencing were not performed, we can only hypothesize on the mechanisms behind the origin of the complex foeto-placental mosaicism we see in seven cases, although there is more strong evidence in the literature as well. WIDER IMPLICATIONS OF THE FINDINGS: Our results have several implications. First, a genome-wide rather than a targeted approach in foetal follow-up examinations after NIPT showing a structural chromosomal aberration is warranted, as other aberrations may be overlooked in the foetus. Second, counselling of pregnant couples after NIPT showing a structural chromosomal aberration should focus not only on the specific aberration detected by NIPT but also on the possibility that the foetus may harbour another, possibly related, structural aberration. Additionally, a structural chromosomal aberration of apparently uncertain significance may unmask truly pathogenic aberrations in the foetus itself, so all potential foetal cases of structural chromosome aberrations should be followed up. Third, we show how comprehensive examinations of the placenta, specifically the separation of CTB and MC, provides crucial insights into the embryonic origins and mechanisms behind structural chromosomal aberrations. Lastly, our results show that complex chromosomal rearrangements as often seen in single-cell studies of pre-implantation embryos, are not artefacts but a biological phenomenon that can actually persist into the mature placenta and foetus. STUDY FUNDING/COMPETING INTEREST(S): Simon H. Thomsen was funded by a private research donation and the Department of Clinical Medicine, Aarhus University. All authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Thomsen SH, van Berkel A, van Veen S, et al. Studies of post-partum placentas provide insights into the origin of structural chromosomal aberrations. Hum Reprod. 2026. PMID: 41338242. doi:10.1093/humrep/deaf235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。